surmount-1 tirzepatide weight loss non-diabetic π Could a new medication help reduce complications of obesity? The SURMOUNT-MMO trial investigates tirzepatide, a dual GIP and GLP-1 receptor agonist, in adults with obesity or overweight but without diabetes. Researchers surmount-1 tirzepatide weight loss non-diabetic
Pay in 4 interest-free payments of $5.49 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours Β· Estimated delivery Oct 16 - Oct 21


























